In vitro diagnosis refers to the collection of body fluids, blood and tissue fluids through the human body, and then determine the disease through clinical diagnosis. Our current test for the new coronavirus is in vitro diagnosis. Therefore, A-share listed companies that can carry out this technology is naturally known as the concept of in vitro diagnostic stocks.
In-vitro diagnostic concept a *** there are 25 listed companies, of which 8 in-vitro diagnostic concept listed companies traded on the SSE, the other 17 in-vitro diagnostic concept listed companies traded on the SZSE.
Currently the global in vitro diagnostics demand market is mainly distributed in North America, Europe, Japan and other developed economies, the United States with a 35% share of the world's largest in vitro diagnostics market, Japan ranked second, accounting for about 7.5%, the developed countries of the European Union is also listed in the world's top ten in vitro diagnostics market, these developed countries, the IVD industry has entered into a relatively stable and mature stage, the annual growth rate is expected to be 5% in the future. The annual growth rate is expected to be around 5% in the future.The global IVD market was about $43.6 billion in 2012 and is expected to reach $58.5 billion by 2018.
China's in vitro diagnostics industry is still in the early stage of industrial development, showing a small base and fast growth rate. China's per capita IVD expenditure for the same period is only 1.5 U.S. dollars, compared with the developed countries there is still a large space for growth, is expected to maintain an annual growth rate of 15-20% in the next few years.
To develop the industry in China, policy support is an indispensable factor. The state has been encouraging and supporting the bio-technology, including in vitro diagnostics, and during the past nine years, the Development and Reform Commission, the State Council, the Ministry of Science and Technology, the Ministry of Health and other departments have issued more than ten relevant support documents.
China in the first 20 years of the 21st century, the country's medium- and long-term scientific and technological development of key areas and its priority themes, "population and health" has become the focus and one of the main areas of priority development, with the country's medical care and security level continues to improve, will further promote in vitro diagnostic industry, the promotion and development of technology, in vitro diagnostics industry, to enjoy the spring breeze of the policy. With the increasing level of national medical protection, it will further promote the promotion and development of in-vitro diagnostic industry technology.
Finally, the in vitro diagnostics industry is currently in the primary stage of development, compared with the mature developed markets, the industry has more room for growth, while the national policy support, it is the rising sunrise industry in China!
Industry stock analysis:
1, the industry's upstream: IVD (in vitro diagnostic) product manufacturing. Foreign companies rely on stable product quality, high technology content and efficient, accurate instrumentation supporting the in vitro diagnostic industry, the market share of more than 50% in the domestic three hospitals occupy a monopoly in the high-end market, the price is generally higher than the domestic similar products 1-5 times.
With the continuous improvement of domestic enterprises' R&D and production technology, the product quality of some enterprises has reached the international advanced level, the market share of domestic products is expanding, and the market is gradually focusing on the leading enterprises, and the concentration of the industry is increasing. At present, the domestic listed companies are represented by these companies: Daan Genetics, Kewa Bio, Lidman, Wanfu Bio, Mike Bio, Meikang Bio and so on.
2, the industry's downstream: for all levels of hospitals, third-party medical laboratories, medical examination institutions, CDC and blood stations and other medical laboratories, the current third medical laboratories, medical examination institutions, the rapid development of the business, the current domestic listed companies are: Dean Diagnostics, Mecox Bio and so on.
3, the industry's midstream: in vitro diagnostic products circulation and service enterprises. At present, there are many in vitro diagnostic product distribution and service enterprises, but most of them are mainly engaged in product distribution, and there are not many enterprises with large scale and high reputation. At present, the domestic listed companies are: Runda Medical, Xinhua Medical, Mike Bio, Meikang Bio, Dean Diagnostics and so on.
In short, the in vitro diagnostic industry is still in the rise of the sunrise industry, stocks have good growth, the market is also positively recognized, these conceptual stocks out of the more powerful bull.